

## AMENDMENTS

***In the specification:***


Please insert the following paragraph at the beginning of the specification, after the title page:

This application is the U.S. national phase of PCT/US00/25408 filed September 15, 2000, which claims priority to U.S. provisional application no. 60/154,639, filed September 17, 1999.

***In the claims:***

Please cancel claims 37-40. Please amend claims 1-12 and 41-47 where specified:


1. (Currently Amended) A compound of the structure:



wherein

R<sup>1</sup> through R<sup>5</sup> contain at least one hydroxyl group ~~phenolic moiety~~ or at least one amine group (NH<sub>2</sub>, ~~NHR<sup>6</sup>~~ NHR<sup>6</sup>, or NR<sup>6</sup>R<sup>7</sup> where R<sup>6</sup> and R<sup>7</sup> are the same or different alkyl having up to 8 carbon atoms), ~~benzyl, or aryl~~ while the remaining R<sup>1</sup> through R<sup>5</sup> are hydrogen.


2. (Currently Amended) A compound of the structure:



wherein

$R^1$  through  $R^5$  contain at least one phosphate ester moiety ( $-\text{OP}(\text{O})(\text{O}^-\text{M}^+)_2$ ) or a phosphoramidate ( $-\text{NP}(\text{O})(\text{O}^-\text{M}^+)_2$ ) where M is a cation or ( $-\text{NP}(\text{O})(\text{OR})_2$ ) where R is an alkyl with up to 8 carbon atoms (the two R groups are the same or different), ~~benzyl, or aryl~~ while the remaining  $R^1$  through  $R^5$  are hydrogen.


3. (Currently Amended) A compound of the structure:



wherein

$R^1$  through  $R^5$  contain at least one phosphate ester moiety ( $-\text{OP}(\text{O})(\text{O}^-\text{M}^+)_2$ ) or a phosphoramidate ( $-\text{NP}(\text{O})(\text{O}^-\text{M}^+)_2$ ) where M is a cation or ( $-\text{NP}(\text{O})(\text{OR})_2$ ) where R is an alkyl with up to 8 carbon atoms (the two R groups are the same or different), ~~benzyl, or aryl~~ while the remaining  $R^1$  through  $R^5$  are hydrogen, and  $R^6$  is hydrogen or alkyl.


4. (Currently Amended) A compound of the structure:



wherein

$R^1$  through  $R^5$  contain at least one hydroxyl phenolic moiety or at least one amine ( $\text{NH}_2$ ,  ~~$\text{NHR}^1$~~ ,  ~~$\text{NHR}^6$~~ , or  $\text{NR}^6\text{R}^7$  where  $R^6$  and  $R^7$  the same or different alkyl having up to 8 carbon atoms, ~~benzyl, or aryl groups~~) while the remaining  $R^1$  through  $R^5$  are a hydrogen.


5. (Currently Amended) A compound of the structure:



wherein

$R^1$  through  $R^5$  contain at least one phosphate ester moiety ( $-\text{OP}(\text{O})(\text{O}^-\text{M}^+)_2$ ) or a phosphoramidate ( $-\text{NP}(\text{O})(\text{O}^-\text{M}^+)_2$ ) where M is a cation or ( $-\text{NP}(\text{O})(\text{OR})_2$ ) where R is an alkyl with up to 8 carbon atoms (the two R groups are the same or different), ~~benzyl, or aryl~~ while the remaining  $R^1$  through  $R^5$  are hydrogen.


6. (Currently Amended) A compound of the structure:



wherein

$R^1$  through  $R^5$  contain at least one phosphate ester moiety ( $-\text{OP}(\text{O})(\text{O}^-\text{M}^+)_2$ ) or a phosphoramidate ( $-\text{NP}(\text{O})(\text{O}^-\text{M}^+)_2$ ) where M is a cation or ( $-\text{NP}(\text{O})(\text{OR})_2$ ) where R is an alkyl with up to 8 carbon atoms (the two R groups are the same or different), ~~or benzyl, or aryl groups~~, while the remaining  $R^1$  through  $R^5$  are a hydrogen and  $R^6$  is hydrogen or alkyl.


7. (Currently Amended) A compound of the structure:



wherein

$R^1$  through  $R^5$  contain at least one hydroxyl group ~~phenolic moiety~~ or at least one amine group ( $NH_2$ ,  ~~$NHR^6$~~  or  $NR^6R^7$  where  $R^6$  and  $R^7$  are the same or different alkyl having up to 8 carbon atoms ~~may be the same or different~~), or benzyl, or aryl groups) while the remaining  $R^1$  through  $R^5$  are a hydrogen.


8. (Currently Amended) A compound of the structure:



wherein

$R^1$  through  $R^5$  contain at least one phosphate ester ( $-OP(O)(O^+M)_2$ ) or a phosphoramidate ( $-NP(O)(O^+M)_2$ ) where  $M$  is a cation or ( $-NP(O)(OR)_2$ ) where  $R$  is an alkyl with up to 8 carbon atoms (the two  $R$  groups are the same or different), ~~benzyl,~~ or aryl while the remaining  $R^1$  through  $R^5$  are hydrogen.


9. (Currently Amended) A compound of the structure:



wherein

$R^1$  through  $R^5$  contain at least one phosphate ester ( $-\text{OP}(\text{O})(\text{O}^-\text{M}^+)_2$ ) or phosphoramidate ( $-\text{NP}(\text{O})(\text{O}^-\text{M}^+)_2$ ) where M is a cation or ( $-\text{NP}(\text{O})(\text{OR})_2$ ) where R is an alkyl with up to 8 carbon atoms (the two R groups are the same or different), benzyl, or aryl, while the remaining  $R^1$  through  $R^5$  are hydrogen, and  $R^6$  is hydrogen or alkyl.


10. (Currently Amended) A compound of the structure:



wherein

$R^1$  through  $R^5$  contain at least one hydroxyl group phenolic moiety or at least one amine group ( $\text{NH}_2$ ,  $\text{NHR}^6$ , or  $\text{NR}^6\text{R}^7$  where  $R^6$  and  $R^7$  are the same or different alkyl having up to 8 carbon atoms, benzyl, or aryl) while the remaining  $R^1$  through  $R^5$  are a hydrogen.


11. (Currently Amended) A compound of the structure:



wherein

$R^1$  through  $R^5$  contain at least one phosphate ester  $(-OP(O)(O^+M)_2)$  or a phosphoramidate  $(-NP(O)(O^+M)_2)$  where M is a cation or  $(-NP(O)(OR)_2)$  where R is an alkyl with up to 8 carbon atoms (the two R groups are the same or different), benzyl, or aryl, while the remaining  $R^1$  through  $R^5$  are hydrogen.


12. (Currently Amended) A compound of the structure:




wherein

$R^1$  through  $R^5$  contain at least one phosphate ester moiety  $(-OP(O)(O^+M)_2)$  or a phosphoramidate  $(-NP(O)(O^+M)_2)$  where M is a cation or  $(-NP(O)(OR)_2)$  where R is an alkyl with up to 8 carbon atoms (the two R groups are the same or different), benzyl, or aryl while the remaining  $R^1$  through  $R^5$  are hydrogen, and  $R^6$  is hydrogen or alkyl.


13. (Original) A compound of the structure:




14. (Original) A compound of the structure:




15. (Original) A compound of the structure:




16. (Original) A compound of the structure:




17. (Original) A compound of the structure:




18. (Original) A compound of the structure:



19. (Original) A compound of the structure:




20. (Original) A compound of the structure:







21. (Original) A compound of the structure:




22. (Original) A compound of the structure:




23. (Original) A compound of the structure:




24. (Original) A compound of the structure:




25. (Original) A compound of the structure:




26. (Original) A compound of the structure:




27. (Original) A compound of the structure:




28. (Original) A compound of the structure:




29. (Original) A compound of the structure:




30. (Original) A compound of the structure:




31. (Original) A compound of the structure:




32. (Original) A compound of the structure:




33. (Original) A compound of the structure:




34. (Original) A compound of the structure:



35. (Original) A compound of the structure:



36. (Original) A compound of the structure:



37. (Cancelled)
38. (Cancelled)
39. (Cancelled)
40. (Cancelled)
41. (Currently Amended) A method for inhibiting tubulin polymerization by contacting a cell tubulin-containing system with an effective amount of a compound described in any one of claims 1-~~36~~40.
42. (Currently amended) The method of claim 41 wherein said cell system is ~~in~~ a tumor cell.
43. (Currently Amended) A method of treating a mammal ~~host~~ afflicted with a neoplastic disease by administering to said mammal ~~host~~ a therapeutically effective amount of a compound described in any one of claims 1-~~36~~40.
44. (Currently Amended) The method of claims 41, wherein the contacted cell system is located in a patient.
45. (Currently Amended) ~~The method of claim 41 described further as for~~ A method for treating cancer by administering to a patient in need thereof, a therapeutically effective amount of a compound described in any one of claims 1-36, wherein said cancer is selected from the group consisting of ~~may be chosen from the group containing~~ leukemia, lung cancer, colon cancer, thyroid cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, pancreatic cancer, and breast cancers.

46. (Currently Amended) A ~~preparation for pharmaceutical use containing~~ pharmaceutical composition comprising a compound from any one of claims 1-~~3640~~ as an active component along with a pharmaceutically acceptable carrier.
47. (Currently Amended) A method for selectively ~~targeting and~~ destroying tumor vasculature in a patient comprising administering an effective amount of a compound described in any one of claims 1-~~3640~~.